James Raftery: The judicial review of NICE’s appraisal of drugs for secondary treatment of osteoporosis

The report of this judgment made me laugh out loud several times. Mr Justice Holman twice describes proceedings  as “bizarre”. A key confidentiality agreement with Dr Kanis  could not be found. “Perceived conflicts of interest” led the  removal of  Dr Kanis  from NICE’s Guideline Development Group. Dr Kanis  went on to make a statement expressly […]

Read More…

Julian Sheather on the case of Naomi Campbell

Naomi Campbell is more often associated with toppling heels and fashion-pack tantrums than fundamental clashes in human rights, but as we all know, in our celebrity-strewn culture, fame can be a lightning rod, drawing down great matters on otherwise unremarkable souls. While there may be more moving sights than the gyrations of exposure-hungry models seeking […]

Read More…

NICE and the influenza antivirals for healthy adults – No, again and again and again

NICE’s  latest technology appraisal of the  flu antiviral drugs (amantadine, oseltamivir and zanamivir), published in February 2009  marks the sixth time these drugs have been considered. The timelines are  shown below. […]

Read More…

“Just doing my job,” by Liz Wager

Determining the appropriate authorship of publications causes all sorts of problems (in part, I believe, because none of the available guidelines apply in all situations, and many journals offer little help – but I’ve written about that elsewhere, so I’ll try not to rant about it here). What I wanted to write about was the […]

Read More…

Richard Smith asks who is the E O Wilson of medicine?

A friend has written to me asking whom I think might be the “E O Wilson of Medicine,” and I’m stumped. Perhaps some readers of the BMJ have never heard of E O Wilson. For those that haven’t he is a Harvard biologist who has twice won the Pullitzer Prize and who invented “consilience,” the […]

Read More…

Julian Sheather on opening the data floodgates

The Coroners and Justice Bill is currently in Committee stage in the UK House of Commons. Section 152 of the Bill amends the Data Protection Act. It gives ministers of state the power to enable the sharing of any data that falls within their sphere of responsibility. It defines data sharing as both “the disclosure […]

Read More…